Empagliflozin – reducing heart failure
Empagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, did not show significant benefit in reducing a first heart failure (HF) hospitalization
5 June 2024
Menu
Empagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, did not show significant benefit in reducing a first heart failure (HF) hospitalization
Unveil the future of healthcare with private GP services tailored for the fast-paced lives of London’s professionals, where flexibility and
Discover how the integration of private healthcare services can be transformative in managing and preventing lifestyle diseases and take control
Explore how private GP services can become a cornerstone in your family healthcare routine, offering personalised attention and comprehensive care
Embark on your next adventure with confidence by ensuring you’re up-to-date with essential travel vaccinations, a key step in planning
Expert Health Advice to Address Your Most Common Health Concerns: Navigate your health journey with confidence through expert insights on